絞り込み

16546

広告

VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy.

著者 Onions K , Gamez M , Buckner NR , Baker SL , Betteridge KB , Desideri S , Dallyn BP , Ramnath R , Neal CR , Farmer LK , Mathieson PW , Gnudi L , Alitalo K , Bates DO , Salmon AHJ , Welsh GI , Satchell SC , Foster RR
Diabetes.2018 Nov 02 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (14view , 0users)

Full Text Sources

Elevated levels of vascular endothelial growth factor (VEGF)A are thought to cause glomerular endothelial cell (GEnC) dysfunction and albuminuria in diabetic nephropathy. We hypothesized that VEGFC could counteract these effects of VEGFA to protect the glomerular filtration barrier and reduce albuminuria. Isolated glomeruli were stimulated with VEGFC, which reduced VEGFA- and type II diabetes-induced glomerular albumin permeability (Ps'alb). VEGFC had no detrimental effect on glomerular function when over-expression was induced locally in podocytes (podVEGFC) in otherwise healthy mice. Further, these mice had reduced glomerular VEGFA mRNA expression, yet increased glomerular VEGF receptor heterodimerization indicating differential signalling by VEGFC. In a model of type I diabetes, induction of podocyte VEGFC over-expression reduced the development of hypertrophy, albuminuria, loss of GEnC fenestrations and protected against altered VEGF receptor expression. In addition, VEGFC protected against raised Ps'alb by endothelial glycocalyx disruption in glomeruli. In summary VEGFC; reduced the development of diabetic nephropathy; prevented VEGF receptor alterations in the diabetic glomerulus; promoted both glomerular protection and endothelial barrier function. These important findings highlight a novel pathway for future investigation in the treatment of diabetic nephropathy.
PMID: 30389746 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード